IL4R and nonpapillary renal cell carcinoma: The IL4Rα-positivity had a 4.3-fold (95% CI; 1.753–10.713) greater risk of death and a 2.7-fold (95% CI; 1.372–5.422) greater risk of relapse or death of CCRCC patients (Table 3).